| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/31/2006 | WO2006091702A2 Multimediator dopamine transport inhibitors, and uses related thereto |
| 08/31/2006 | WO2006091697A1 Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications |
| 08/31/2006 | WO2006091692A1 Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| 08/31/2006 | WO2006091674A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 08/31/2006 | WO2006091671A1 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors |
| 08/31/2006 | WO2006091669A1 Anti-cancer and anti-microbial oxazolidinones and analogues |
| 08/31/2006 | WO2006091661A1 Compositions for and methods of modulating platelet levels |
| 08/31/2006 | WO2006091656A1 Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof |
| 08/31/2006 | WO2006091647A2 Method of preferentially inducing the biosynthesis of interferon |
| 08/31/2006 | WO2006091646A2 Small molecule inhibitors of mdm2 and uses thereof |
| 08/31/2006 | WO2006091592A1 Naphthalene derivatives as modulators of the glucocorticoid receptor |
| 08/31/2006 | WO2006091591A1 Methods of treating gastrointestinal inflammation |
| 08/31/2006 | WO2006091587A2 Use of minoxidil sulfate as an anti-tumor drug |
| 08/31/2006 | WO2006091571A2 Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol |
| 08/31/2006 | WO2006091568A2 Hydroxyalkyl substituted imidazonaphthyridines |
| 08/31/2006 | WO2006091567A2 Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| 08/31/2006 | WO2006091552A1 Dosage and method for attaining beneficial levels of vitamin d3 |
| 08/31/2006 | WO2006091544A2 Methods and compositions for modulating calcium channels |
| 08/31/2006 | WO2006091542A2 Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier |
| 08/31/2006 | WO2006091534A1 Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| 08/31/2006 | WO2006091529A2 A solid pharmaceutical dosage formulation |
| 08/31/2006 | WO2006091522A2 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| 08/31/2006 | WO2006091515A2 Tumour vaccines |
| 08/31/2006 | WO2006091505A2 Neuropeptide y receptor agonists |
| 08/31/2006 | WO2006091496A2 Benzazole potentiators of metabotropic glutamate receptors |
| 08/31/2006 | WO2006091450A1 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| 08/31/2006 | WO2006091442A2 Transdermal systems having control delivery system |
| 08/31/2006 | WO2006091428A2 Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
| 08/31/2006 | WO2006091394A2 Substituted imidazoquinolines and imidazonaphthyridines |
| 08/31/2006 | WO2006091246A1 Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| 08/31/2006 | WO2006091187A1 Isoflavonoids for preventing radiation- and chemotherapy- induced weight loss |
| 08/31/2006 | WO2006091160A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 08/31/2006 | WO2006091112A1 Compositions for the delivery of rna interference molecules and methods for their use |
| 08/31/2006 | WO2006091034A1 A composition for treating stroke comprising carboxylate derivative |
| 08/31/2006 | WO2006091033A1 Composition for reducing the exudation of serum proteins |
| 08/31/2006 | WO2006091010A1 Composition comprising coenzyme q10 as effective ingredient |
| 08/31/2006 | WO2006091009A1 Pharmaceutical composition for the treatment of cancer comprising lmh-ra complex |
| 08/31/2006 | WO2006090999A1 Anhydrous sibutramine malates and preparation method thereof |
| 08/31/2006 | WO2006090935A1 Acerola fruit-derived pectin and use thereof |
| 08/31/2006 | WO2006090932A1 Surrogate marker for sulfonamide compound |
| 08/31/2006 | WO2006090931A1 Novel concomitant use of sulfonamide compound with anti-cancer agent |
| 08/31/2006 | WO2006090930A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | WO2006090928A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| 08/31/2006 | WO2006090927A1 Orexigenic action of sulfonamide compound |
| 08/31/2006 | WO2006090921A1 Inhibitory effect of sulfonamide compound on lymphocyte activation |
| 08/31/2006 | WO2006090920A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATING RECEPTOR δ |
| 08/31/2006 | WO2006090915A1 Pyridyl acetic acid compounds |
| 08/31/2006 | WO2006090910A1 Novel steroid glycoside, ngf-associated active substance, process for producing the same, method of screening thereof, and cerebral dysfunction preventive agent |
| 08/31/2006 | WO2006090906A1 NOVEL METHOD FOR OVERCOMING RNAi-RESISTANT STRAIN OF VIRUS |
| 08/31/2006 | WO2006090900A1 Preventives/remedies for cancer |
| 08/31/2006 | WO2006090853A1 Nitrogenous heterocyclic compound and medicinal use thereof |
| 08/31/2006 | WO2006090850A1 Benzamide compound |
| 08/31/2006 | WO2006090848A1 Method for detection of nucleotide polymorphism in gene used for diagnosing effect of methotrexate therapy in rheumatoid arthritis patient |
| 08/31/2006 | WO2006090845A1 Method for producing granules |
| 08/31/2006 | WO2006090839A1 Medicine for external application containing anti-inflammatory agent and soy lecithin |
| 08/31/2006 | WO2006090833A1 Transdermal preparation for external use containing nonsteroidal antiinflammatory/analgesic agent |
| 08/31/2006 | WO2006090830A1 Method of producing proanthocyanidin oligomer |
| 08/31/2006 | WO2006090817A1 Indole compound and use thereof |
| 08/31/2006 | WO2006090815A1 Agent for preventing development of prion disease, food additive and feed additive comprising the same |
| 08/31/2006 | WO2006090813A1 Element retained in blood showing degradability selectively in tumor tissue |
| 08/31/2006 | WO2006090782A1 Composition for hydrous adhesive patch for external use and adhesive patch comprising the composition |
| 08/31/2006 | WO2006090768A1 Process for production of optically active ppar-activating compound and intermediate of the same |
| 08/31/2006 | WO2006090759A1 Pharmaceutical agent comprising solifenacin |
| 08/31/2006 | WO2006090756A1 Novel preventive or remedy for lipid metabolism disorder, obesity and diabetes and use therefor |
| 08/31/2006 | WO2006090745A1 Neurotization promoting agent |
| 08/31/2006 | WO2006090743A1 1-(2h)-isoquinolone derivative |
| 08/31/2006 | WO2006090717A1 Quinazoline derivative having tyrosine kinase inhibitory activity |
| 08/31/2006 | WO2006090699A1 Preventive or therapeutic agent for cardiac dysfunction or myocardial damage caused by ischemia or ischemia-reperfusion |
| 08/31/2006 | WO2006090698A1 Kinase inhibitor and use thereof |
| 08/31/2006 | WO2006090640A1 Tablet composition containing amino acid and process for producing tablet |
| 08/31/2006 | WO2006090616A1 Fat cell differentiation regulator |
| 08/31/2006 | WO2006090613A1 Hair cosmetic |
| 08/31/2006 | WO2006090557A1 Preventive or therapeutic agent for stroke or sequelae of stroke comprising as main component salvianolic acid b or the like |
| 08/31/2006 | WO2006090494A1 Anticancer agent |
| 08/31/2006 | WO2006090376A2 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone |
| 08/31/2006 | WO2006090285A1 Ocaperidone salts and pharmaceutical compositions containing the same |
| 08/31/2006 | WO2006090279A1 Oxyindole derivatives as 5ht4 receptor agonists |
| 08/31/2006 | WO2006090275A1 Treatment of incontinence |
| 08/31/2006 | WO2006090274A1 Crystalline acat inhibitor |
| 08/31/2006 | WO2006090273A2 [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| 08/31/2006 | WO2006090272A1 Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
| 08/31/2006 | WO2006090270A1 Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir |
| 08/31/2006 | WO2006090268A2 Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin |
| 08/31/2006 | WO2006090263A1 Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions |
| 08/31/2006 | WO2006090261A1 Bicyclic heteroaromatic derivatives useful as anticancer agents |
| 08/31/2006 | WO2006090250A1 Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-prop an-2-ol compounds |
| 08/31/2006 | WO2006090244A1 New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them |
| 08/31/2006 | WO2006090234A1 Heterocyclic derivatives as cell adhesion inhibitors |
| 08/31/2006 | WO2006090224A1 Benzisoxazole derivatives |
| 08/31/2006 | WO2006090206A1 Improved extracts of psidium guajava l., methods for its obtaining and use for the treatment of gastrointestinal disorders |
| 08/31/2006 | WO2006090192A1 Medicaments for alzheimer |
| 08/31/2006 | WO2006090177A1 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE |
| 08/31/2006 | WO2006090169A1 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| 08/31/2006 | WO2006090167A2 Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| 08/31/2006 | WO2006090163A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 08/31/2006 | WO2006090150A1 Pharmaceutical composition comprising amorphous rosiglitazone |
| 08/31/2006 | WO2006090143A1 4-0x0quinaz0lin-3-yl benzamide derivatives for the treatment of cytokine diseases |
| 08/31/2006 | WO2006090142A1 l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST |
| 08/31/2006 | WO2006090129A2 Bicalutamide for delivering increasing steady state plasma levels |
| 08/31/2006 | WO2006090094A1 Pyrimidothiophene compounds for use as hsp90 inhibitors |